John C. Byrd, MD

John C. Byrd, MD, discusses the early results and adverse events observed in the ELEVATE-RR trial in patients with chronic lymphocytic leukemia.

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

John C. Byrd, MD, from OSUCCC – James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).